185 related articles for article (PubMed ID: 37439384)
1. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.
Pisano MD; Sun F; Cheng Y; Parashar D; Zhou V; Jing X; Sompallae R; Abrudan J; Zimmermann MT; Mathison A; Janz S; Pufall MA
Haematologica; 2023 Dec; 108(12):3372-3383. PubMed ID: 37439384
[TBL] [Abstract][Full Text] [Related]
2. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
3. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.
Hofgaard PO; Jodal HC; Bommert K; Huard B; Caers J; Carlsen H; Schwarzer R; Schünemann N; Jundt F; Lindeberg MM; Bogen B
PLoS One; 2012; 7(12):e51892. PubMed ID: 23284805
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
[TBL] [Abstract][Full Text] [Related]
5. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
[TBL] [Abstract][Full Text] [Related]
6. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
7. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.
Fairfield H; Dudakovic A; Khatib CM; Farrell M; Costa S; Falank C; Hinge M; Murphy CS; DeMambro V; Pettitt JA; Lary CW; Driscoll HE; McDonald MM; Kassem M; Rosen C; Andersen TL; van Wijnen AJ; Jafari A; Reagan MR
Cancer Res; 2021 Feb; 81(3):634-647. PubMed ID: 33218968
[TBL] [Abstract][Full Text] [Related]
8. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
[TBL] [Abstract][Full Text] [Related]
9. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
10. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
11. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
[TBL] [Abstract][Full Text] [Related]
12. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Tai YT; Acharya C; An G; Moschetta M; Zhong MY; Feng X; Cea M; Cagnetta A; Wen K; van Eenennaam H; van Elsas A; Qiu L; Richardson P; Munshi N; Anderson KC
Blood; 2016 Jun; 127(25):3225-36. PubMed ID: 27127303
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
Front Immunol; 2021; 12():667054. PubMed ID: 34149703
[TBL] [Abstract][Full Text] [Related]
14. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Yaccoby S; Barlogie B; Epstein J
Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577
[TBL] [Abstract][Full Text] [Related]
15. [BAFF level in bone marrow and expression of BAFF receptor on B cells in multiple myeloma patients].
Zhou ZH; Zhang L; Pan QY; Huang BH; Zheng D; Liu JR; Li J; Luo SK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1131-4. PubMed ID: 23114133
[TBL] [Abstract][Full Text] [Related]
16. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
[TBL] [Abstract][Full Text] [Related]
17. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
18. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
[TBL] [Abstract][Full Text] [Related]
19. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
20. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
